Compare Manulife Financial Corporation (MFC) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Stryker Corporation — how do they compare? Manulife Financial Corporation trades at $43.58 (market cap $69.48B), while Stryker Corporation trades at $276.85 (market cap $106.24B). The key difference: Stryker Corporation is the larger of the two by market cap, and Manulife Financial Corporation pays the higher dividend (3.23%). Which is the better fit depends on your goals — on Pluang, investors hold Manulife Financial Corporation for 119 Days and Stryker Corporation for 20 Days on average.
| MFC | SYK | |
|---|---|---|
Market Cap | $69.48B | $106.24B |
Volume | 1,347,508 | 2,982,001 |
Sector | Financials | Health |
52-Week High | $44.77 | $388.35 |
52-Week Low | $31.64 | $269.75 |
Typical Hold Time | 119 Days | 20 Days |
Enterprise Value | $64.75B | $117.70B |
Dividend Yield | 3.23% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manulife Financial (MFC) trades at $41.67, down 2.94% with bearish technical signals despite strong fundamentals. The company reported solid Q2 2026 earnings of $0.79 per share, beating expectations, with revenue growth to $53.01 billion in 2025 and improving cash flow trends. Recent institutional investments from Bank of America and executive appointments signal confidence in long-term strategy.
MFC presents a mixed outlook with strong profitability metrics (11.7% net margin, 13.88% ROE) and analyst consensus favoring Buy ratings (57%), but faces technical headwinds and premium valuation concerns. The stock trades above the $34.24 consensus target, suggesting limited near-term upside despite operational strength and dividend stability.
Stryker Corporation (SYK) trades at $275.40, down 1.11% amid bearish technical signals and recent negative news regarding manufacturing issues. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $3.69 versus $3.49 expected, and profitability metrics remain robust with a 14.43% net income margin. Analyst consensus remains overwhelmingly bullish with a $368.11 price target representing 33% upside potential.
Despite near-term headwinds from manufacturing disclosures and legal investigations, Stryker's solid earnings track record, strong cash flow generation, and dominant medical technology position support long-term growth prospects. Key risks include ongoing legal scrutiny and competitive pressures in the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
